An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: Effects of citalopram, escitalopram and sertraline

Human Psychopharmacology

Volumn 23, Issue 3, 2008, Pages 231-241

  Guille, Valérie ^a   Croft, Rodney J ^a   O'Neill, Barry V ^a   Illic, Susan ^a   Phan, K Luan ^b   Nathan, Pradeep J ^c,d  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Citalopram; Escitalopram; Loudness dependence auditory evoked potential; Selective serotonin reuptake inhibitor; Serotonin; Sertraline

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO; SEROTONIN; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; HUMAN; HUMAN EXPERIMENT; LOUDNESS DEPENDENCE OF THE AUDITORY EVOKED POTENTIAL; MALE; NEUROLOGIC EXAMINATION; NEUROTRANSMISSION; NON INVASIVE MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; VALIDITY;

ADOLESCENT; ADULT; AFFECT; AUDITORY CORTEX; BEHAVIOR; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY; HUMANS; MALE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SYNAPTIC TRANSMISSION;

EID: 42549167530     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.922     Document Type: Article

References (62)

1. Artigas F. 1993.5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 14: 262-263.
2. Baribeau JC, Laurent J. 1987. The effect of selective attention on augmenting/intensity function of the early negative waves of AEP's. Electroencephalogr Clin Neurophysiol S40: 68-75.
3. Barth DS, Di S. 1990. Three-dimensional analysis of auditory-evoked potentials in rat neocortex. J Neurophysiol 64(5): 1527-1536.
4. Berlanga C, Flores-Ramos M. 2006. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95(1-3): 119-123.
5. Bond A, Lader M. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218.
6. Brown S, Martinez MJ, Hodges DA, Fox PT, Parsons LM. 2004. The song system of the human brain. Brain Res Cogn Brain Res 20: 363-375.
7. Buchsbaum M, Goodwin F, Murphy D, Borge G. 1971. AER in affective disorders. Am J Psychiatry 128: 51-57.
8. Carrillo-de-la-Pena MT. 1999. Effects of intensity and order of stimuli presentation on AEP's: an analysis of the consistency of EP augmenting/ reducing in the auditory modality. Clin Neurophysiol 110: 924-932.
9. Chen TJ, Yu YW, Chen MC, Tsai SJ, Hong CJ. 2002. Association analysis for serotonin transporter promoter polymorphism and auditory evoked potentials for major depression. Neuropsychobiology 46: 57-60.
10. Connolly JF. 1987. ERPs suggest the importance of subcortical mechanisms in activities typically associated with cortical functions. Electroencephalogr Clin Neurophysiol 40: 635-644.
11. Cremers T, Westerink B. 2003. Pharmacological difference between escitalopram and citalopram. Int J Psychiatr Clin Prac 7: 306.
12. Croft RJ, Klugman A, Baldeweg T, Gruzelier JH. 2001. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("Ecstasy") users. Am J Psychiatry 158: 1687-1692.
13. Croft RJ, Barry RJ. 2000. EOG correction of blinks with saccade coefficients: a test and revision of the aligned-artefact average solution. Clin Neurophysiol 111: 444-451.
14. Debener S, Strobel A, Kurschner K, et al. 2002. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? Biol Psychology 59:121-133.
15. DeVane CL, Liston HL, Markowitz JS. 2002. Clinical pharmacokinetics of sertraline (review). Clin Pharmacokinetics 41(15): 1247-1266.
16. Dierks T, Barta S, Demisch L, et al. 1999. Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects. Psychopharmacology 146: 101-107.
17. Fuchs M, Drenckhahn R, Wischmann HA, Wagner M. 1998. An improved boundary element method for realistic volume-conductor modeling. IEEE Trans Biomed Eng 45: 980-997.
18. Gallinat J, Senkowski D, Wernicke C, et al. 2003. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology 28: 530-532.
19. Gallinat J, Bottlender R, Juckel G, et al. 2000. The loudness dependence of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology 148: 404-411.
20. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. 2002. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology 163(1): 106-110.
21. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. 2003. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28(1): 148--152.
22. Hegerl U, Gallinat J, Juckel G. 2001. Event-related potentials: Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62: 93-100.
23. Hegerl U, Herrmann WM, Ulrich G, Müller-Oerlinghausen B. 1990. Effects of lithium on auditory evoked potentials in healthy subjects. Biol Psychiatry 27: 555-560.
24. Hegerl U, Juckel G, Mackert A. 1991. Auditory evoked potentials and clinical response to antidepressive treatment with fluvoxamine. Biol Psychiatry 29: 602S.
25. Hegerl U, Juckel G, Schmidt LG, Rommelspacher H. 1996. Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Psychiatry Res 63: 47-455.
26. Hegerl U, Juckel G. 1993. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 33: 173-187.
27. Hegerl U, Prochno I, Ulrich G, Müller-Oerlinghausen B. 1989. Sensation seeking and auditory evoked potentials. Biol Psychiatry 25: 179-190.
28. Hegerl U, Gallinat J, Mrowinski D. 1994. Intensity dependence of auditory evoked dipole source activity. Int J Psychophysiol 17: 1-13.
29. Hensch T, Wargelius HL, Herold U, Lesch KP, Oreland L, Brocke B. 2006. Further evidence for an association of 5-HTTLPR with intensity dependence of auditory-evoked potentials. Neuropsychopharmacology 31(9): 2047-2054.
30. Hubbard RB, Judd LL, Huey LY. 1979. Evoked potential augmentation and reduction phenomena in alcoholics and normals maintained on lithium carbonate. Psychopharmacol Bull 15(1): 46-47.
31. Hyttel J. 1994. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1): 19-26.
32. Hyvarinen A, Oja E. 2000. Independent component analysis: algorithms and applications. Neural Netw 13:411-430.
33. 1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 21: 710-716.
34. Juckel G, Molnár M, Hegerl U, Csepe V, Karmos G. 1997. Auditory-evoked potentials as indicator of brain serotonergic activity - first evidence in behaving cats. Biol Psychiatry 41: 1181-1195.
35. Kahkonen S, Jaaskelainen IP, Pennanen S, Liesivuori J, Ahveninen J. 2002. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. Psychopharmacology 164: 221-227.
36. Kemp AH, Nathan PJ. 2004a. Acute augmentation of serotonin suppresses cardiovascular responses to emotional valence. Int J Neuropsychopharmacol 7(1): 65-70.
37. Kemp AH, Gray MA, Silberstein RB, Armstrong SM, Nathan PJ. 2004b. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage 22(3): 1084-1096.
38. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. 2005. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25: 318-324.
39. Knight RT, Brailowsky S. 1990. Auditory evoked potentials from the primary auditory cortex of the cat: topographic and pharmacological studies. Electroencephalogr Clin Neurophysiol 77: 225-232.
40. Massey AE, March VR, McAllister-Williams RH. 2004. Lack of effect of tryptophan depletion in the loudness dependency of auditory event related potentials in healthy volunteers. Biol Psychology 65: 137-145.
41. Mitzdorf U. 1985. Current source-density method and application in cat cerebral cortex: investigation of evoked potentials and EEG phenomena. Physiol Rev 65: 37-91.
42. Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M. 2001. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88(5): 282-286.
43. Mork A, Kreilgaard M, Sanchez C. 2003. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45(2): 167-173.
44. Morrison J, Foote SL, Molliver ME, Bloome FE, Lidov HGW. 1982. Noradrenergic and serotonergic fibres innervate complementary layers in monkey primary visual cortex: an immunohistochemical study. Proc Natl Acad Sci USA 79: 2401-2405.
45. Mulert C, Juckel G, Augustin H, Hegerl U. 2002. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol 113: 1566-1572.
46. Nadeem HS, Attenburrow MJ, Cowen PJ. 2004. Comparison of the effects of citalopram and escitalopram on 5-Ht-Mediated Neuroendocrine Responses. Neuropsychopharmacol 29(9): 1699-1703.
47. Nishizawa S, Benkelfat C, Young SN, et al. 1997. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94: 5308-5313.
48. Nathan PJ, Segrave R, Phan KL, O' Neill B, Croft RJ. 2006. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol 21: 47-52.
49. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. 2004. Escitalopram versus citalopram: the surprising role of the R-enantiomer (review). Psychopharmacology 174(2): 163-176.
50. Scherg M, Picton TW. 1991. Separation and identification of event-related potential components by brain electric source analysis. Electroencephalogr Clin Neurophysiol S42: 24-37.
51. Scherg M, Von Cramon D. 1986. Evoked dipole source potentials of the human auditory cortex. Electroencephalogr Clin Neurophysiol 65: 344-360.
52. Schroeder CE, Tenke CE, Givre SJ, Arezzo JC, Vaughan HG Jr. 1990. Laminar analysis of bicuculline-induced epileptiform activity in area 17 of the awake macaque. Brain Res 515: 326-330.
53. Senkowski D, Linden M, Zubragel D, Bar T, Gallinat J. 2003. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol Psychiatry 53: 304-314.
54. Simmons JG, Allen NB, Berger G, Nathan PJ. 2003. The influence of chronic sertraline administration on the loudness dependence of the auditory evoked potential in healthy subjects. Psychophysiology 40: S80.
55. Strobel A, Debener S, Schmidt D, Huunerkopf R, Lesch KP, Brocke B. 2003. Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet Part B (Neuropsychiatr Genet) 118B: 41-47.
56. Tuchtenhagen F, Daumann J, Norra C, et al. 2000. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 22: 608-617.
57. Uhl I, Gorynia I, Gallinat J, et al. 2006. Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects? Hum Psychopharmacol 21(7): 463-472.
58. Von Knorring L, Perris C. 1981. Biochemistry of the augmenting/reducing response in visual evoked potentials. Neuropsychobiology 7: 1-8.
59. Waugh J, Goa KL. 2003. Escitalopram. A review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17(5): 343-362.
60. Wilson MA, Molliver ME. 1991. The organization of serotonergic projections to cerebral cortex in primates: retrograde transport studies. Neuroscience 44: 537-553.
61. Zemon V, Kaplan E, Ratliff F. 1986. The role of GABA-mediated intracortical inhibition in the generation of visual evoked potentials. In Cracco RQ, Bodis-Wollner I (eds.). Evoked potentials, Liss, New York; 287-295.
62. Zuckerman M. 1988. Sensation seeking and behavioural disorders. Arch Gen Psychiatry 45: 502-504.